Prognostic value of miR‑1181 in non‑small cell lung cancer and its regulatory effect on tumor progression

Liu,Feng; Ma,Guodong; Wang,Bo; Wang,Xiang; Huang,Chenjun

doi:10.3892/etm.2021.10719

Prognostic value of miR‑1181 in non‑small cell lung cancer and its regulatory effect on tumor progression

Authors:
- Feng Liu
- Guodong Ma
- Bo Wang
- Xiang Wang
- Chenjun Huang
View Affiliations

Affiliations: Department of Chest Surgery, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, P.R. China, Department of Oncology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221000, P.R. China, Department of Thoracic Surgery, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, P.R. China
Published online on: September 13, 2021 https://doi.org/10.3892/etm.2021.10719
Article Number: 1284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is one of the most important causes of cancer‑related death. miR‑1181 has been reported to have roles in various cancer types and its function in the progression of NSCLC was investigated in the present study. A total of 118 patients with NSCLC were recruited and their tumor tissues were collected. The expression of miR‑1181 in NSCLC tissues and cells was detected by reverse transcription‑quantitative PCR. The prognostic value of miR‑1181 was evaluated by Kaplan‑Meier and Cox regression analysis and the roles of miR‑1181 in cell proliferation, migration and invasion of NSCLC were analyzed by Cell Counting Kit‑8 and Transwell assays. miR‑1181 was indicated to be upregulated in NSCLC tissues and cell lines, and to be associated with lymph node metastasis and the TNM stage of patients. Patients with high miR‑1181 expression had a poorer prognosis than those with low miR‑1181 expression. miR‑1181 levels and TNM stage were determined to be two independent prognostic factors for NSCLC. In addition, overexpression of miR‑1181 exerted enhancing effects on cell proliferation, migration and invasion of NSCLC, while its knockdown inhibited these cellular processes. In conclusion, upregulation of miR‑1181 in NSCLC was associated with lymph node metastasis and TNM stage of patients and was indicative of poor prognosis. miR‑1181 was indicated to exert promoting effects on cell proliferation, migration and invasion of NSCLC cells and to be involved in tumor progression, providing novel insight for the development of biomarkers and therapies for NSCLC.

View Figures

View References

1	Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 37 (Suppl 8):S4–S66. 2001.PubMed/NCBI View Article : Google Scholar
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
3	Bilfinger T, Keresztes R, Albano D and Nemesure B: Five-year survival among stage IIIA lung cancer patients receiving two different treatment modalities. Med Sci Monit. 22:2589–2594. 2016.PubMed/NCBI View Article : Google Scholar
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
5	Minna JD, Roth JA and Gazdar AF: Focus on lung cancer. Cancer Cell. 1:49–52. 2002.PubMed/NCBI View Article : Google Scholar
6	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015.PubMed/NCBI View Article : Google Scholar
7	Yang J, Zhang Z, Chen S, Dou W, Xie R and Gao J: miR-654-3p predicts the prognosis of hepatocellular carcinoma and inhibits the proliferation, migration, and invasion of cancer cells. Cancer Biomark. 28:73–79. 2020.PubMed/NCBI View Article : Google Scholar
8	Wang M, Qiu R, Gong Z, Zhao X, Wang T, Zhou L, Lu W, Shen B, Zhu W and Xu W: miR-188-5p emerges as an oncomiRNA to promote gastric cancer cell proliferation and migration via upregulation of SALL4. J Cell Biochem. 120:15027–15037. 2019.PubMed/NCBI View Article : Google Scholar
9	Tang X, Ding Y, Wang X, Wang X, Zhao L and Bi H: miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway. Oncol Lett. 18:4621–4628. 2019.PubMed/NCBI View Article : Google Scholar
10	Luo J, Pan J, Jin Y, Li M and Chen M: miR-195-5p Inhibits proliferation and induces apoptosis of non-small cell lung cancer cells by targeting CEP55. Onco Targets Ther. 12:11465–11474. 2019.PubMed/NCBI View Article : Google Scholar
11	Zhong K, Chen K, Han L and Li B: MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. BMC Cancer. 14(703)2014.PubMed/NCBI View Article : Google Scholar
12	Hu Y, Wang L, Gu J, Qu K and Wang Y: Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. Oncotarget. 8:74554–74566. 2017.PubMed/NCBI View Article : Google Scholar
13	Wang J, Guo XJ, Ding YM and Jiang JX: miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. World J Gastroenterol. 23:1594–1601. 2017.PubMed/NCBI View Article : Google Scholar
14	Zhang HY, Li JH, Li G and Wang SR: Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer. Oncol Rep. 34:1193–1202. 2015.PubMed/NCBI View Article : Google Scholar
15	Song Z, Yu Z, Chen L, Zhou Z, Zou Q and Liu Y: MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1. Biomed Pharmacother. 119(109397)2019.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Cai Z, Li J, Zhuang Q, Zhang X, Yuan A, Shen L, Kang K, Qu B, Tang Y, Pu J, et al: MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-β1 and IL-6/STAT3 signaling pathways. Exp Mol Med. 50:1–11. 2018.PubMed/NCBI View Article : Google Scholar
18	Benderska N, Dittrich AL, Knaup S, Rau TT, Neufert C, Wach S, Fahlbusch FB, Rauh M, Wirtz RM, Agaimy A, et al: miRNA-26b overexpression in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis. 21:2039–2051. 2015.PubMed/NCBI View Article : Google Scholar
19	Pao W: New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc. 9:72–73. 2012.PubMed/NCBI View Article : Google Scholar
20	Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M, et al: An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA. 101:9740–9744. 2004.PubMed/NCBI View Article : Google Scholar
21	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.PubMed/NCBI View Article : Google Scholar
22	Yoon JS, Kim G, Lee YR, Park SY, Tak WY, Kweon YO, Park JG, Lee HW, Han YS, Ha HT, et al: Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark Med. 12:1105–1114. 2018.PubMed/NCBI View Article : Google Scholar
23	Wang D, Lu G, Shao Y and Xu D: MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway. Biomed Pharmacother. 99:334–339. 2018.PubMed/NCBI View Article : Google Scholar
24	Feng Y, Yang C, Hu D, Wang X and Liu X: miR-675 promotes disease progression of non-small cell lung cancer via activating NF-κB signaling pathway. Cell Mol Biol (Noisy-le-grand). 63:7–10. 2017.PubMed/NCBI View Article : Google Scholar
25	Liu H, Ma Y, Liu C, Li P and Yu T: Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression. Open Biol. 8(180118)2018.PubMed/NCBI View Article : Google Scholar
26	Shao C, Yang F, Qin Z, Jing X, Shu Y and Shen H: The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: A systematic review with meta-analysis. BMC Cancer. 19(1103)2019.PubMed/NCBI View Article : Google Scholar
27	An JX, Ma ZS, Ma MH, Shao S, Cao FL and Dai DQ: MiR-1236-3p serves as a new diagnostic and prognostic biomarker for gastric cancer. Cancer Biomark. 25:127–132. 2019.PubMed/NCBI View Article : Google Scholar
28	Peng X, Pan X, Liu K, Zhang C, Zhao L, Li H, Guan X, Xu W, Xu J, Zhang F and Lai Y: miR-142-3p as a novel biomarker for predicting poor prognosis in renal cell carcinoma patients after surgery. Int J Biol Markers. 34:302–308. 2019.PubMed/NCBI View Article : Google Scholar
29	Wang Y, Jiang F, Wang J, Fu Y, Li Y and Li F: MiR-519a functions as a tumor suppressor and is negatively associated with poor prognosis of non-small cell lung cancer. Cancer Biomark. 28:121–128. 2020.PubMed/NCBI View Article : Google Scholar
30	Zhang Y and Xu H: Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients. J Clin Lab Anal. 34(e23237)2020.PubMed/NCBI View Article : Google Scholar
31	Fan L, Wang J, Cao Q, Ding X and Li B: Aberrant miR-1246 expression promotes radioresistance in non-small cell lung cancer: A potential prognostic biomarker and radiotherapy sensitization target. Am J Cancer Res. 10:314–335. 2020.PubMed/NCBI
32	Jiang J, Li Z, Yu C, Chen M, Tian S and Sun C: MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Cancer Lett. 356:962–970. 2015.PubMed/NCBI View Article : Google Scholar
33	Ning L, Zhang M, Zhu Q, Hao F, Shen W and Chen D: miR-25-3p inhibition impairs tumorigenesis and invasion in gastric cancer cells in vitro and in vivo. Bioengineered. 11:81–90. 2020.PubMed/NCBI View Article : Google Scholar
34	Soheilyfar S, Velashjerdi Z, Sayed Hajizadeh Y, Fathi Maroufi N, Amini Z, Khorrami A, Haj Azimian S, Isazadeh A, Taefehshokr S and Taefehshokr N: In vivo and in vitro impact of miR-31 and miR-143 on the suppression of metastasis and invasion in breast cancer. J BUON. 23:1290–1296. 2018.PubMed/NCBI